8.00 Welcome Coffee

8:50 am Chair’s Opening Remarks

The Next Golden Ticket: Achieving Targeted & Extrahepatic Delivery

9:00 am Exploring a Next-Gen Delivery Platform for Targeted Delivery: Fusogenix Proteo-Lipid Vehicle (PLV)

  • John Lewis Founder & Chief Executive Officer , Entos Pharmaceuticals

Synopsis

  • Combining low-toxicity profiles of neutral lipids and high efficacy of fusogenic protein-mediated delivery technology
  • Achieving active targeting of extrahepatic tissues through targeted FAST proteins
  • Applications in DNA therapeutics

9:30 am Multiplexed Screening of LNPs in Vivo Enabled by Nucleic Acid Barcoding

  • Cory Sago Senior Director & Head of LNP Discovery , Beam Therapeutics

Synopsis

  • 100s of LNPs can be tested in vivo in the same experiment using barcoding technologies
  • Application of these screening technologies for identification of LNPs for extrahepatic cell-types
  • Discussion on development of HSC-tropic LNPs

10:00 am Fireside Chat

  • John Lewis Founder & Chief Executive Officer , Entos Pharmaceuticals
  • Cory Sago Senior Director & Head of LNP Discovery , Beam Therapeutics
  • James Ferguson Chief Medical Officer , Matinas BioPharma

Synopsis

Join this casual discussion with key leaders in lipid-based nanoparticle delivery to hear their opinions on the key areas of opportunity, how close we are to targeted delivery and what the key next steps this industry needs to take to achieve this. Get involved by asking your burning questions.

10.40 Structured Networking & Morning Coffee Break

Synopsis

Meet and connect with your peers in this dedicated networking session

Transforming Design to Overcome Toxicity, Tolerability & Immunogenicity

11:30 am Roundtable Discussion: Improving Cross-Functional Collaboration

Synopsis

To design and develop a best-in-class delivery vehicle, insight from biologists, chemists and engineers are needed.
As well as this, collaboration across payload innovators and vehicle innovators is crucial to overcome payload-specific hurdles.
Join this roundtable to discuss as a community on how cross-functional collaboration can be improved to continue driving progression in this field to harness the full potential of lipid-based carriers.

12.15 Lunch Break

Synopsis

Take this chance to meet the expert speakers, connect with your peers and explore our exhibition booths

Navigating New Payloads & Advanced Delivery

1:15 pm Predictive High-Throughput Screening of Oligonucleotide Lipid Nanoparticles

Synopsis

  • Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles
  • Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing
  • Expandable applications and screening for other RNA therapeutics

1:45 pm Elevating Clinical Design for a Lipid Nanoparticle Candidate

Synopsis

  • Navigating a successful journey into clinic
  • Assessing the considerations for an LNP delivered therapeutic
  • Insights into patient selection and clinical design

2:15 pm Challenges in Translating Innovative Gene Therapy Drug Targets for Accelerated Development & IND/BLA Submissions

  • Hemant Kumar Chief Technology & Manufacturing Officer , Genprex

Synopsis

  • Managing vision and mission of a clinical stage company keeping ‘Patients First’ in mind
  • Risk assessment models for scalability and GMP Manufacturing
  • Identification of right CDMO as a strategic partner for the success to retain the lead position as an ‘Innovator’ in the competitive market

2:45 pm Chair’s Closing Remarks & End of Summit